Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P02794 (
ferritin
)
17,525
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Intracellular
ferritin
in newt (Triturus cristatus) erythroblasts was accessible to the chelating effects of EDTA and pyridoxal phosphate. EDTA (0.5-1 mM) promoted release of radioactive iron from
ferritin
of pulse-labelled erythroblasts during chase incubation, but its continuous presence was not necessary for
ferritin
iron mobilization. Brief exposure to EDTA was sufficient to release 60-70% of
ferritin
59Fe content during ensuing chase in EDTA-free medium. EDTA also suppressed cellular iron uptake and utilization for heme synthesis, but these activities were restored upon its removal.
Pyridoxal
-5'-phosphate (0.5-5 mM) also stimulated loss of radioactive iron from
ferritin
; however,
ferritin
iron release by pyridoxal phosphate required its continued presence. Unlike EDTA, pyridoxal phosphate did not interfere with iron uptake or its utilization for heme synthesis. Chelator-mobilized
ferritin
iron accumulated initially in the hemolysate as a low-molecular-weight component and appeared to be eventually released into the medium. No radioactive
ferritin
was found in the medium of chelator-treated cells, indicating that secretion or loss of
ferritin
was not responsible for decreasing cellular
ferritin
59Fe content. Moreover, there was no transfer of radioactive iron between the low-molecular-weight component released into the medium and plasma transferrin. These results indicate that chelator-released
ferritin
iron is not available for cellular utilization in heme synthesis and that
ferritin
iron released by this process is not an alternative or complementary iron source for heme synthesis. Correlation of these data with effects of succinylacetone inhibition of heme synthesis and with previous studies indicates that the main role of erythroid cell
ferritin
is absorption and storage of excess iron not used for heme synthesis.
...
PMID:Mobilization of ferritin iron in erythroblasts by chelating agents. 391 75
Pyridoxal
isonicotinoyl hydrazone (PIH) and several analogues were synthesized and assessed in the rat hepatocyte culture for their potential in iron chelation therapy.
Pyridoxal
isonicotinoyl hydrazone and pyridoxal benzoyl hydrazone were as effective as desferrioxamine (DFO) in reducing both net uptake of rat transferrin-59Fe and incorporation into
ferritin
by hepatocytes. Dialysis studies showed that this was due to a cellular action and not to the extracellular chelation of transferrin-bound 59Fe. The analogues of PIH were more effective in mobilization studies than PIH and DFO, releasing more 59Fe from
ferritin
as well as from the stroma-mitochondrial membranes in hepatocytes prelabelled using transferrin-59Fe. Chelator action was dependent on incubation time, concentration, temperature and lipophilicity.
Pyridoxal
benzoyl hydrazone, the most effective iron chelator, was also the most lipophilic, suggesting that access to cellular iron compartments as well as iron-binding affinity is important in effective iron chelation.
...
PMID:Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. 403 21